MedDay’s Phase 3 Trial - impact on Optic Neuritis failed
MedDay’s MD-1003 PHASE III Optic Neuritis Trial Results For MS
A clinical trial of MedDay’s promising medication MD-1003 in a study of the drugs impact on Optic Neuritis failed to meet its endpoint in outperforming placebo towards improving vision for people who have multiple sclerosis.
Here is a link to the article (from May 10, 2017 ):
http://www.msunites.com/meddays-md-1003 ... ts-for-ms/
On a positive note, they are reporting positive results for patients with Progressive Multiple Sclerosis (although only 12.6% of patients taking MD1003 (biotin) had an improvement in their EDSS score.)